Corient Private Wealth LP Invests $985,000 in ICU Medical, Inc. $ICUI

Key Points

• Corient Private Wealth initiated a $985,000 position in ICU Medical, purchasing 6,716 shares during the second quarter. Institutional investors collectively own 96.1% of the company, with several major firms also adding or initiating positions.
• ICU Medical reported quarterly EPS of $2.37, beating consensus estimates of $1.91, while revenue reached $547.9 million. Revenue increased 0.5% year over year, and the company maintained fiscal 2026 EPS guidance of $8.60–$9.00.
• Analyst sentiment remains positive overall, with a “Moderate Buy” consensus and an average price target of $192.80 versus the reported share price of $167.58. However, insiders sold 21,830 shares worth approximately $3.9 million over the past 90 days.

Corient Private Wealth LP purchased a new stake in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,716 shares of the medical instruments supplier's stock, valued at approximately $985,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. BlackRock Inc. bought a new position in ICU Medical in the 2nd quarter valued at about $550,250,000. Jupiter Topco LLC bought a new stake in shares of ICU Medical during the 2nd quarter worth about $407,786,000. Millennium Management LLC lifted its stake in shares of ICU Medical by 173.4% in the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier's stock worth $130,638,000 after acquiring an additional 690,694 shares during the period. Norges Bank acquired a new stake in shares of ICU Medical in the 4th quarter worth approximately $58,083,000. Finally, Bank of America Corp DE bought a new position in shares of ICU Medical in the second quarter valued at approximately $54,059,000. 96.10% of the stock is currently owned by institutional investors.

Insider Transactions at ICU Medical

In other ICU Medical news, Director Elisha Finney sold 378 shares of the company's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $182.48, for a total value of $68,977.44. Following the transaction, the director owned 4,871 shares of the company's stock, valued at approximately $888,860.08. This represents a 7.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel Woolson sold 5,417 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $181.33, for a total value of $982,264.61. Following the sale, the vice president owned 17,062 shares of the company's stock, valued at $3,093,852.46. This trade represents a 24.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 21,830 shares of company stock valued at $3,905,003 in the last 90 days. 2.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently commented on ICUI. Zacks Research lowered shares of ICU Medical from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 28th. Raymond James Financial restated a "strong-buy" rating and issued a $200.00 target price on shares of ICU Medical in a research report on Friday, August 7th. Sanford C. Bernstein lowered ICU Medical to a "market perform" rating in a research note on Monday, June 15th. Needham & Company LLC increased their price target on ICU Medical from $165.00 to $187.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Finally, Piper Sandler lifted their price target on ICU Medical from $163.00 to $195.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, ICU Medical presently has an average rating of "Moderate Buy" and an average target price of $192.80.

ICU Medical Stock Performance

NASDAQ:ICUI opened at $167.58 on Friday. ICU Medical, Inc. has a twelve month low of $112.50 and a twelve month high of $192.85. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. The company has a 50-day moving average of $167.35 and a 200-day moving average of $144.86. The firm has a market cap of $4.19 billion, a price-to-earnings ratio of 142.02, a price-to-earnings-growth ratio of 2.12 and a beta of 0.75.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts' consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The business had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same period in the previous year, the firm earned $2.10 EPS. The business's revenue for the quarter was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Analysts forecast that ICU Medical, Inc. will post 7.19 earnings per share for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source